Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine

References

• WiendlHToykaKVRieckmannPBasic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendationsJ Neurol2008255101449146319005625
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trialNeurology19934346556618469318
   PubMed Web of Science ®Google Scholar
• PatyDWLiDKInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study GroupNeurology19934346626678469319
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study GroupRandomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosisLancet19983529139149815049820297
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group and the University of British Columbia MS/MRI Analysis GroupPRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MSNeurology200156121628163611425926
   PubMed Web of Science ®Google Scholar
• LiDKPatyDWMagnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by Interferon-beta1a subcutaneously in multiple sclerosisAnn Neurol199946219720610443885
   PubMed Web of Science ®Google Scholar
• LiuCBlumhardtLDRandomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curvesJ Neurol Neurosurg Psychiatry199967445145610486390
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trialNeurology1995457126812767617181
   PubMed Web of Science ®Google Scholar
• ComiGFilipiMWolinskyJSfor the European/Canadian Glatiramer Acetate Study GroupEuropean/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosisAnn Neurol20014929029711261502
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol19963932852948602746
   PubMed Web of Science ®Google Scholar
• SimonJHJacobsLDCampionMMagnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupAnn Neurol19984379879450771
   PubMed Web of Science ®Google Scholar
• HartungHPHigh-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosisExpert Opin Pharmacother20091029130919236200
   PubMed Web of Science ®Google Scholar
• PerumalJFilippiMFordCGlatiramer acetate therapy for multiple sclerosis: a reviewExpert Opin Drug Metab Toxicol200621019102917125414
   PubMed Web of Science ®Google Scholar
• FrancisGBenefit-risk assessment of interferon-beta therapy for relapsing multiple sclerosisExpert Opin Drug Saf2004328930315268647
   PubMedGoogle Scholar
• DurelliLVerdunEBarberoPIndependent Comparison of Interferon (INCOMIN) Trial Study GroupEvery-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)Lancet20023591453146011988242
   PubMed Web of Science ®Google Scholar
• MikolDDBarkhofFChangPComparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialLancet Neurol200871090391418789766
   PubMed Web of Science ®Google Scholar
• CadavidDWolanskyLJSkurnickJEfficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME studyNeurology200972231976198319279320
   PubMed Web of Science ®Google Scholar
• O’ConnorPFilippiMArnasonB250 mug or 500 mug interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyLancet Neurol200981088989719729344
   PubMed Web of Science ®Google Scholar
• BarberoPBerguiMVersinoEINCOMIN Trial Study GroupEvery-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with NabMult Scler200612727616459722
   PubMed Web of Science ®Google Scholar
• SchwidSRThorpeJShariefMEVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group; University of British Columbia MS/MRI Research Group. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE StudyArch Neurol20056278579215883267
   PubMed Web of Science ®Google Scholar
• PanitchHGoodinDSFrancisGEVIDENCE Study GroupEVidence of Interferon Dose-response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE TrialNeurology2002591496150612451188
   PubMed Web of Science ®Google Scholar
• PanitchHGoodinDFrancisGEVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trialJ Neurol Sci2005239677416169561
   PubMed Web of Science ®Google Scholar
• LublinFDWhen marketing and science intersect: do patients with MS benefit?Neurology2002591480148112451185
   PubMed Web of Science ®Google Scholar
• KieburtzKMcDermottMNeeded in MS: Evidence, not EVIDENCENeurology2002591482148312451186
   PubMed Web of Science ®Google Scholar
• CohenBARieckmannPEmerging oral therapies for multiple sclerosisInt J Clin Pract2007611922193017784852
   PubMed Web of Science ®Google Scholar
• RíoJPorcelJTéllezNFactors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosisMult Scler20051130630915957512
   PubMed Web of Science ®Google Scholar
• CoxDStoneJManaging self-injection difficulties in patients with relapsing-remitting multiple sclerosisJ Neurosci Nurs20063816717116817668
   PubMedGoogle Scholar
• CohenBAAdherence to disease-modifying therapy for multiple sclerosisInt J MS Care2006Suppl3237
   Google Scholar
• CramerJACuffelBJDivanVPatient satisfaction with an injection device for multiple sclerosis treatmentActa Neurol Scand200611315616216441244
   PubMed Web of Science ®Google Scholar
• TremlettHLOgerJInterrupted therapy: stopping and switching of the beta-interferons prescribed for MSNeurology20036155155412939437
   PubMed Web of Science ®Google Scholar
• RansohoffRMNatalizumab for multiple sclerosisN Engl J Med2007356252622262917582072
   PubMed Web of Science ®Google Scholar
• RiceGPAHartungHCalabresiPAAnti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationaleNeurology20056481336134215851719
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• RudickRAStuartWHCalabresiPANatalizumab plus interferon beta-1a for relapsing multiple sclerosisN Engl J Med2006354991192316510745
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMastersBKTylerKLProgressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosisN Engl J Med2005353436937415947079
   PubMed Web of Science ®Google Scholar
• Langer-GouldAAtlasSWGreenAJBollenAWPelletierDProgressive multifocal leukoencephalopathy in a patient treated with natalizumabN Engl J Med2005353437538115947078
   PubMed Web of Science ®Google Scholar
• Van AsscheGVan RanstMSciotRProgressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s diseaseN Engl J Med2005353436236815947080
   PubMed Web of Science ®Google Scholar
• HartungHNew cases of progressive multifocal leukoencephalopathy after treatment with natalizumabLancet Neurol200981283119081511
   PubMed Web of Science ®Google Scholar
• LindåHvon HeijneAMajorEOProgressive multifocal leukoencephalopathy after natalizumab monotherapyN Engl J Med20093611081108719741229
   PubMed Web of Science ®Google Scholar
• WenningWHaghikiaALaubenbergerJTreatment of progressive multifocal leukoencephalopathy associated with natalizumabN Engl J Med20093611075108019741228
   PubMed Web of Science ®Google Scholar
• MolloyESCalabreseLHTherapy: targeted but not trouble-free: efalizumab and PMLNat Rev Rheumatol20095841841919648939
   PubMed Web of Science ®Google Scholar
• CarsonKREvensAMRicheyEAProgressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports projectBlood20091134834484019264918
   PubMed Web of Science ®Google Scholar
• ColesAJCompstonDASSelmajKWAlemtuzumab vs interferon beta-1a in early multiple sclerosisN Engl J Med2008359171786180118946064
   PubMed Web of Science ®Google Scholar
• KieseierBCWiendlHOral disease-modifying treatments for multiple sclerosis: the story so farCNS Drugs200721648350217521228
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
   PubMed Web of Science ®Google Scholar
• GiovannoniGComiGCookSA placebo-controlled trial of oral cladribine for relapsing multiple sclerosisN Engl J Med2010362541642620089960
   PubMed Web of Science ®Google Scholar
• KapposLRadueEO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
   PubMed Web of Science ®Google Scholar
• CarrollWMOral therapy for multiple sclerosis – sea change or incremental step?N Engl J Med2010362545645820089958
   PubMed Web of Science ®Google Scholar
• CarsonDAWassonDBTaetleRYuASpecific toxicity of 2 chlorodeoxyadenosine toward resting and proliferating human lymphocytesBlood1983627377436136305
   PubMed Web of Science ®Google Scholar
• CarsonDAKayeJSeegmillerJELymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s)Proc Natl Acad Sci U S A19777456775681202960
   PubMed Web of Science ®Google Scholar
• SipeJCCladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosisExpert Rev Neurother201010336537520187859
   PubMed Web of Science ®Google Scholar
• LiliemarkJThe clinical pharmacokinetics of cladribineClin Pharmacokinet1997321201319068927
   PubMed Web of Science ®Google Scholar
• KawasakiHCarreraCJPiroLDSavenAKippsTJCarsonDARelationship of deoxycytidine kinase and cytoplasmic 50-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosineBlood1993815976018094016
   PubMed Web of Science ®Google Scholar
• GriffigJKoobRBlakleyRLMechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cellsCancer Res198949692369282573423
   PubMed Web of Science ®Google Scholar
• RieckmannPComiGCookSEffects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96 week, Phase III, double-blind, placebo-controlled CLARITY study. Meeting Abstract. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Duesseldorf, Germany, 2009 Sep 9–12Mult Scler200915S248S249
   Google Scholar
• SalvatCCurchodMLGuedjECellular expression profiling of genes involved in the cladribine metabolic pathway: insights into mechanism of action in multiple sclerosisProcedings and Abstracts of the Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)Dusseldorf, Germany2009 Sep 9–12 (Poster presentation P280).
   Google Scholar
• RiceGPFilippiMComiGCladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study GroupNeurology2000541145115510720289
   PubMed Web of Science ®Google Scholar
• HartungHAktasOKieseierBGiancarlo ComiGCDevelopment of oral cladribine for the treatment of multiple sclerosisJ Neurol2010257216317019921304
   PubMed Web of Science ®Google Scholar
• Soelberg-SorensenPComiGCookSEffects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis (RRMS) in the 96 week, phase III, double-blind, placebo-controlled CLARITY study. Meeting Abstract. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, Germany, 2009 Sep 9–12Mult Scler200915S137
   Google Scholar
• KopadzeTDobertMLeussinkVIDehmelTKieseierBCCladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosisEur J Neurol20091640941219175384
   PubMed Web of Science ®Google Scholar
• Mitosek-SzewczykKStelmasiakZBartosik-PsujekHBelniakEImpact of cladribine on soluble adhesion molecules in multiple sclerosisActa Neurol Scand2010 [Epub ahead of print]
   Web of Science ®Google Scholar
• JaniecKWajgtAKondera-AnaszZEffect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosisMed Sci Monit20017939811208501
   PubMedGoogle Scholar
• Bartosik-PsujekHBelniakEMitosek-SzewczykKDoboszBStelmasiakZInterleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribineActa Neurol Scand200410939039215147461
   PubMed Web of Science ®Google Scholar
• LaugelBChallierJSiegfriedCChvatchkoYWeissertRGalibertLCladribine exerts a modulatory effect of T cell activationMult Scler200814S52S53
   Google Scholar
• JuliussonGChristiansenIHansenMMOral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemiaJ Clin Oncol199614216021668683250
   PubMed Web of Science ®Google Scholar
• OguraMMorishimaYKobayashiYDurable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin’s lymphomas: results of a Japanese phase II studyInt J Hematol20048026727715540903
   PubMed Web of Science ®Google Scholar
• SavenAPiroLD2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignanciesAnn Intern Med19941207847917908507
   PubMed Web of Science ®Google Scholar
• SchirmerMMurEPfeifferKPThalerJKonwalinkaGThe safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trialScand J Rheumatol1997263763799385350
   PubMed Web of Science ®Google Scholar
• DavisJCJrAustinHIIIBoumpasDA pilot study of 2-chloro-20-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritisArthritis Rheum1998413353439485092
   PubMed Web of Science ®Google Scholar
• BeutlerESipeJCRomineJSKoziolJAMcMillanRZyroffJThe treatment of chronic progressive multiple sclerosis with cladribineProc Natl Acad Sci U S A199693171617208643695
   PubMed Web of Science ®Google Scholar
• RomineJSSipeJCKoziolJAZyroffJBeutlerEA double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosisProc Assoc Am Physicians199911135449893155
   PubMedGoogle Scholar
• LeistTPVermerschPThe potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulationCurr Med Res Opin2007232667267617880754
   PubMed Web of Science ®Google Scholar
• McDonaldWICompstonAEdanGRecommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosisAnn Neurol20015012112711456302
   PubMed Web of Science ®Google Scholar
• KurtzkeJFRating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS)Neurology198333144414526685237
   PubMed Web of Science ®Google Scholar
• PolmanCHReingoldSCEdanGDiagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Ann Neurol200558684084616283615
   PubMed Web of Science ®Google Scholar
• ChesonBDVenaDABarrettJFreidlinBSecond malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemiasJ Clin Oncol1999172454246010561309
   PubMed Web of Science ®Google Scholar
• KurzrockRStromSSEsteyESecond cancer risk in hairy cell leukemia: analysis of 350 patientsJ Clin Oncol199715180318109164188
   PubMed Web of Science ®Google Scholar
• CookSA combined analysis of data from four randomized, double-blind, placebo-control led trials of parenteral cladribine and one open-label pilot study to assess the safety and tolerability profile of repeated periods of cladribine treatment in patients with progressive or relapsing multiple sclerosis (P02. 180)Neurology American Academy of Neurology MeetingChicago2008
   Google Scholar
• KapposLAntelJComiGOral fingolimod (FTY720) for relapsing multiple sclerosisN Engl J Med2006355111124114016971719
   PubMed Web of Science ®Google Scholar
• O’ConnorPWLiDFreedmanMSA phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology200666689490016567708
   PubMed Web of Science ®Google Scholar
• PolmanCBarkhofFSandberg-WollheimMTreatment with laquinimod reduces development of active MRI lesions in relapsing MSNeurology200564698799115781813
   PubMed Web of Science ®Google Scholar
• KapposLGoldRMillerDHEfficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet200837296481463147218970976
   PubMed Web of Science ®Google Scholar